Latest news with #Ainos
Associated Press
10 hours ago
- Business
- Associated Press
Water Tower Research Highlights Ainos' AI Nose Accuracy Breakthrough in Elderly Care Monitoring: SmellTech Gets Smarter
PRESS RELEASE: Paid Content from ACCESS Newswire. The AP news staff was not involved in its creation. AI Nose accuracy in elderly care improved to 85% with additional Smell ID training AI-friendly healthcare policies to provide tailwinds for commercial rollout SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 3, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ... Published [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] AI Nose accuracy in elderly care improved to 85% with additional Smell ID training AI-friendly healthcare policies to provide tailwinds for commercial rollout SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 3, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ('Ainos' or the 'Company'), a leader in AI-powered scent digitization, today announced that Water Tower Research ('WTR') has published a report highlighting a significant milestone in the Company's AI Nose project for elderly care. AI Nose has reached approximately 85% accuracy in excretion odor detection-improving over the recently met internal milestone of 80%. Key Highlights from the Report: AI Nose Accuracy enhanced through machine learning at scale: The improved accuracy is based on 254 subject events and 2,119 sample entries in Japan and Taiwan. WTR estimates AI Nose achieved ~92% sensitivity, supporting the platform's reliability for real-time hygiene monitoring in long-term care environments. Data-driven machine learning and AI model training contribute to the improved accuracy, underscoring AI Nose's ability to enhance detection with increased data input. Addressing aging population challenges in Japan and Taiwan: AI Nose offers a timely and scalable solution to the rising demand for senior care driven by the aging populations of Japan and Taiwan. In Japan, nearly 30% of the population is aged 65 or older, a figure projected to rise to 35% by 2040-creating an anticipated shortfall of ~570,000 caregivers. In Taiwan, the elderly population is expected to exceed 20% by 2025, with one of the world's lowest birthrates. AI-integrated healthcare policy tailwinds support AI Nose adoption: AI Nose is strategically aligned with major AI-friendly healthcare digital transformation initiatives, including Japan's Society 5.0 and HealthcareDX frameworks and Taiwan's long-term care programs. These policy tailwinds are expected to accelerate commercialization pathways and generate scalable demand for AI Nose in high-need healthcare settings. Commercial rollout targeted for 2026, with scalable Asia-Pacific growth potential: Ainos is advancing toward commercial deployment of AI Nose in long-term care facilities in 2026, following pilot testing through the second half of 2025. This timeline positions Ainos to capture early-mover advantage in Japan's aging population segment, with expansion opportunities in other Asian regions, reflecting AI Nose's scalability and regional relevance in addressing healthcare labor shortages and chronic care demands. Pioneering SmellTech in $29.8-billion E-nose market: Ainos is positioning AI Nose as a category-defining SmellTech platform at the leading edge of the $29.8 billion global electronic nose market in 2025. By combining proprietary AI models with advanced gas sensor arrays, AI Nose is designed to unlock new, data-driven applications across healthcare, industrial, and robotics sectors. This differentiated approach positions Ainos as a potential first mover in digitized scent detection, with scalable upside across high-growth verticals. Read the Full Water Tower Research Report Here: About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit . Follow Ainos on X, formerly known as Twitter, ( @AinosInc ) and LinkedIn to stay up-to-date. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shen [email protected] SOURCE: Ainos, Inc. press release
Associated Press
5 days ago
- Business
- Associated Press
Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80%
Accelerating Toward Commercial Rollout as AI Nose Solves Critical Gaps in Elder Care SAN DIEGO, CA / ACCESS Newswire / May 29, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ('Ainos'), a leader in AI-powered scent digitization, announced today that its proprietary AI Nose platform achieved approximately 85% accuracy in detecting excretion odors data, an improvement from 80% previously, based on collected from 254 participant instances in Japan and Taiwan, resulting in 2119 valid entries for subsequent statistical evaluation. The milestone validates AI Nose as a deploy able solution for non-contact hygiene monitoring in long-term care (LTC) and positions Ainos to lead the emerging SmellTech category. SmellTech for Digitized, AI-Powered Long-term Care AI Nose digitizes scent into Smell IDs using MEMS gas sensors and proprietary AI models harnessing 13 years of scent data across healthcare and industrial use-cases. Its compact, embedded-ready design enables seamless integration into portable devices, ambient monitors, or robotic platforms. Ainos is aiming to address the aging population by aligning with government efforts to digitize aging care and reduce institutional burden. Ainos targets high-impact use cases in long-term care for seniors, including: Japan and Taiwan Face Alarming Demographic Pressure Japan and Taiwan are doubling down on robotic and AI-assisted care through initiatives like Society 5.0, Healthcare DX, and Taiwan's Long-Term Care 2.0. Ainos' AI Nose aims to support these national priorities by delivering precision, automation, and labor cost relief. Commercial Rollout Timeline Ainos is also partnering with Japan's leading service robotics company to embed AI Nose into autonomous robots, bringing olfaction into smart care infrastructure for the first time. SmellTech: A $76.5B Opportunity by 2032 Ainos is pioneering SmellTech as a new category of machine perception. The global electronic nose market is forecast to grow from $29.8B in 2025 to $76.5B by 2032, at a 14.4% CAGR, with growing use in healthcare. With solid validation, real-world deployment in progress, and deep IP, Ainos is positioned to capture first-mover advantage in this rapidly scaling sector. Human-Centric Vision and Corporate Responsibility 'I believe AI Nose is a new sensory layer for healthcare,' said Chun-Hsien (Eddy) Tsai, Chairman, President and CEO of Ainos. 'We design this platform to meet real human needs: protecting dignity, reducing labor pressure, and enabling smarter aging care. With Japan and Taiwan both facing demographic cliffs, this milestone proves that smell-driven automation can be a game-changer.' While Ainos pursues innovation and commercialization, the development of its bio-inspired electronic nose technology is fundamentally guided by a humanitarian mission. The company is dedicated to enhancing the quality of life for the elderly, alleviating long-term societal care burdens, and promoting dignity and harmony within caregiving environments and families. 'We may be a technology company, but our purpose is deeply human,' said Tsai. 'AI Nose represents more than a breakthrough in digital scent-it's Ainos' promise to confront the aging crisis with compassion and to protect the dignity of those we love.' About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit Follow Ainos on X, formerly known as Twitter, ( @AinosInc ) and LinkedIn to stay up-to-date. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shen [email protected] SOURCE: Ainos, Inc. press release
Associated Press
30-04-2025
- Business
- Associated Press
Ainos Forms Partnership with ASE's Key Site to Power AI-Driven SmellTech in Semiconductor Smart Manufacturing
Expanding AI Nose's Commercial Opportunity for Smarter, Safer, and More Sustainable Factories SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 30, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ('Ainos' or the 'Company'), a leader in AI-driven scent digitization, has announced it has formed a strategic partnership with ASE Chung Li ('ASECL') - a key site of Advanced Semiconductor Engineering, Inc., the world's leading provider of semiconductor assembly and test services. This new milestone expands the joint effort to power AI scent digitization in smart manufacturing. Under a legally binding Memorandum of Understanding (MOU), Ainos and ASECL aims to first optimize AI Nose for ASECL's environment, then strategize to deploy AI Nose in ASECL's operation. ASECL, a member of the ASE Group, delivers comprehensive semiconductor manufacturing services, including engineering test, package design, IC assembly, wafer probing, final test, and design manufacturing services (DMS). Unlocking a New Dimension in Smart Manufacturing Despite the growing sophistication of semiconductor fabs, airborne VOCs (volatile organic compounds) remain a largely untapped source of process insight. These compounds can subtly impact yield, equipment health, and worker safety. Ainos' AI Nose transforms VOC patterns into real-time 'Smell ID' data-enabling intelligent monitoring, predictive analytics, and ESG compliance at scale. How AI Nose Will Enhance Smart Factory Operations: About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit Follow Ainos on X, formerly known as Twitter, ( @AinosInc ) and LinkedIn to stay up-to-date. About ASE Advanced Semiconductor Engineering, Inc. (ASE), a member of ASE Technology Holding Co., Ltd. (NYSE: ASX, TAIEX: 3711) is the leading global provider of semiconductor manufacturing services in assembly and test. Alongside a broad portfolio of established assembly and test technologies, ASE is also delivering innovative VIPack™, advanced packaging, and system-in-package solutions to meet growth momentum across a broad range of end markets, including AI, automotive, 5G, high-performance computing, and more. To learn about our advances in SiP, fanout, MEMS and sensor, flip chip, and 2.5D, 3D and TSV technologies, all ultimately geared towards applications to improve lifestyle and efficiency, please visit: ASE Website, or follow ASE on LinkedIn & X: @aseglobal. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shen [email protected] SOURCE: Ainos, Inc. press release
Associated Press
14-04-2025
- Business
- Associated Press
Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan
Dual Trials Accelerate VELDONA® Toward Rare Disease Market Entry Bridging Strategy Aims to Fast-Track U.S. Regulatory Approvals SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 14, 2025 / Ainos, Inc. (Nasdaq:AIMD, AIMDW) ('Ainos' or the 'Company'), pioneer of low-dose oral interferon therapeutics, today announced significant progress in advancing its oral interferon drug platform, VELDONA® in the rare disease space. The Taiwan Food and Drug Administration (TFDA) has approved the Company's clinical trial for human immunodeficiency virus (HIV)-related oral warts, while Institutional Review Board (IRB) clearance has been granted for its upcoming Sjögren's Syndrome (pSS) study. The upcoming Taiwan trials will be conducted using the Company's next-generation VELDONA® formulation, aiming to confirm efficacy equal to or better than previous results, as well as accelerating US and Taiwan regulatory approval and commercialization. 'The upcoming Taiwan trials using our new formulation aim to confirm efficacy equal to or better than previous results. We are also pursuing bridging consultations with both Food and Drug Administration (FDA) and TFDA. If regulators confirm alignment, we could accelerate market entry through a harmonized approval process. Our partnership with Taiwan Tanabe Seiyaku for manufacturing and market development of our pSS program further strengthens our commercialization pathway,' said Chun-Hsien (Eddy) Tsai, Chairman, President, and CEO of Ainos. 'Ainos is steadily advancing across three core growth pillars: scent digitization with AI Nose technology, AI-powered point-of-care testing powered by AI Nose, and VELDONA®. These strategic pillars form a foundation to our growth. We're executing rapidly and building momentum across the VELDONA® platform. Our ability to launch two Taiwan trials in parallel reflects our dedication to capital efficiency, operational strength and delivering innovative, patient-friendly therapies to the market,' Mr. Tsai added. 'HIV-related oral warts and primary Sjögren's Syndrome both lack effective standard treatments and impose meaningful burdens on quality of life. As an oral therapy, VELDONA® provides a convenient, non-invasive alternative to injectable interferons-especially important for chronic or immune-compromised patients. We believe our previous Phase II and III trials delivered positive results, and we see significant potential for VELDONA® in these indications,' said Dr. Albert Yu, Technical Director of Pharmaceuticals at Ainos. These studies expand Ainos' immunotherapy footprint in underserved rare disease segments, in line with the Company's previously announced development plans. TFDA Approves HIV Oral Warts Trial; Enrollment to Begin in June Ainos' planned trial, titled 'Evaluation of Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-Seropositive Subjects Receiving Combination Anti-Retroviral Therapy' (Protocol ID: 03HUHI19), will be conducted at National Taiwan University Hospital (NTUH). Oral warts are a frequent and painful complication in HIV-positive patients. According to UNAIDS, approximately 39.9 million people globally live with HIV in 2023, with 1.3 million new infections and 630,000 AIDS-related deaths reported that year. Despite prevalence, oral wart treatment remains a poorly addressed niche with limited therapeutic options. The market for managing HIV-related HPV manifestations, including oral warts, is estimated at $500-700 million globally, driven by demand for safer and more tolerable long-term treatments1. Ainos plans to begin the trial in June 2025 and targets completion in 2H 2026. Primary and secondary endpoints will evaluate the efficacy of VELDONA® plus antiretroviral therapy compared to placebo. Bestat Pharmaservices Corporation, a TFDA-accredited contract research organization (CRO), will manage the study under Good Clinical Practice (GCP) standards. IRB Clears Sjögren's Syndrome Trial; TFDA Review in Progress The planned trial, titled 'An Open-Label Study to Evaluate the Efficacy Of VELDONA® in Patients with Primary Sjögren's Syndrome' (Protocol ID: 24PSS01) received IRB approval from Taipei Medical University - Joint IRB on October 25, 2024 (Approval No.: TMU-JIRB N202408042). TFDA submission is underway, with clearance expected in August 2025. Sjögren's Syndrome is a chronic autoimmune disease affecting salivary and tear glands, with limited treatment options. According to National Center for Biotechnology Information (NCBI), the condition affects an estimated 400,000 to 3.1 million people in the U.S. alone, mostly women aged 45-55. The global market for Sjögren's Syndrome therapeutics is projected to reach about $3.3 billion by 2030, driven by rising prevalence and increasing demand for effective therapies2. The trial will take place at Shuang Ho Hospital and evaluate whether VELDONA® improves salivary flow and alleviates dryness symptoms. Secondary endpoints include ESSPRI/ESSDAI scores, symptom-specific VAS ratings, and salivary gland imaging. Ainos aims to initiate site initiation visit (SIV) and first patient first visit (FPFV) in October 2025 and targets to conclude the trial in 1H 2027. ComboTrial Consultancy Ltd, a TFDA-recognized CRO, will manage the trial. Ainos has previously completed three U.S. clinical trials evaluating VELDONA® in pSS. Results showed significant improvement in oral dryness with a favorable safety profile. VELDONA®: Transforming Immunotherapy Through Oral Delivery Harnessing nearly four decades of development, VELDONA® is Ainos' proprietary low-dose oral interferon-alpha platform, designed to activate immune responses via oromucosal delivery. The platform delivers therapeutic benefit at ultra-low doses, minimizing systemic side effects often associated with injectable interferons. By targeting rare and underserved indications, Ainos is positioning VELDONA® as a versatile, scalable solution for chronic autoimmune and infectious diseases across global markets. [1]: Market scope estimate based on various analysis of HPV/HIV co-infection treatment segments. [2]: Market Report Analytics, 'Sjogrens Syndrome Therapeutics Market CAGR Growth Drivers and Trends: Forecasts 2025-2033.' About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify Ainos' commitment to enabling AI with the ability to smell and individuals to live healthier. Ainos' clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. For more information, visit: Follow Ainos on X, formerly known as Twitter, ( @AinosInc ) and LinkedIn to stay up-to-date. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shen [email protected] SOURCE: Ainos, Inc. press release
Yahoo
05-03-2025
- Business
- Yahoo
Ainos and ugo to Develop the World's First Robot With a Sense of Smell
A Major Breakthrough in Ainos' Mission to Digitize Scent First-ever Smell-Enabled Robotics Will Unlock New Revenue Streams in Smart Manufacturing, Public Safety and more SAN DIEGO, CA / / March 5, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW), a pioneer of smell digitization, and ugo, Inc., Japan's largest service robot company by market share1, today announced a strategic partnership to integrate Ainos' AI Nose technology with ugo's autonomous robotic platform. This collaboration will mark a major milestone in the digitization of smell, unlocking new capabilities for robots in industrial safety, healthcare, and public security. AI Nose, originally developed for medical diagnostics, mimics human olfaction by detecting and analyzing volatile organic compounds (VOCs). Backed by nearly a decade of research and a strong patent portfolio, AI Nose has already demonstrated its effectiveness in healthcare and industrial environments. In Japanese semiconductor manufacturing facilities, AI Nose has successfully identified 22 different VOCs with nearly 80% accuracy, proving its potential to enhance real-time safety monitoring and environmental analysis. Pioneering a Breakthrough: Giving Robots the Power to Smell Until now, robots have relied primarily on vision, sound, and touch to perceive their surroundings. Smell has remained an unsolved technological challenge-but Ainos is about to change that. With the integration of AI Nose, ugo robots will gain olfactory perception, enabling them to: Enhance Industrial Safety: Detect gas leaks, identify toxic chemicals, and prevent equipment failures in semiconductor, chemical, and manufacturing plants. Strengthen Public Safety: Assist in security patrols by detecting explosives, narcotics, and hazardous substances in transportation hubs and critical infrastructure. Advance Environmental Monitoring: Provide continuous air quality assessments, detect pollutants, and support smart city initiatives. Transform Healthcare: Analyze VOC samples for early disease detection, support infection control in hospitals, and monitor elderly care facilities for hygiene and health risks. "This partnership will be a defining moment in our journey to digitize smell," said Chun-Hsien (Eddy) Tsai, Chairman, President and CEO of Ainos. "By combining AI Nose's cutting-edge olfactory sensing with ugo's advanced robotics, we will create a new category of intelligent machines that can see, hear, and now-smell." Ken Matsui, Representative Director of ugo, added, "Olfaction is the next frontier in robotics. Integrating AI Nose into our robots will significantly expand their sensory intelligence, making them more effective in real-world applications across industries. Our robots, including ugo Pro, ugo Ex and ugo mini, are deployed in Japanese sectors facing worker shortages, such as security patrols and inspection tasks, in office buildings, data centers, manufacturing plants, and public facilities. By equipping ugo robots with AI-driven scent detection, we are taking automation to the next level-providing intelligent solutions that improve workplace safety, environmental monitoring, and healthcare support." Exploring the Future of Robotics with AI-Powered Scent Detection By exploring the integration of AI Nose into ugo's robotic platform, there is potential to create new revenue opportunities through various business models: Technology Licensing & Hardware Sales: Ainos will license AI Nose technology to ugo, enabling ugo to offer premium olfaction-enabled robots. Robotics-as-a-Service (RaaS): Businesses can deploy AI Nose-equipped ugo robots through subscription-based models for continuous air monitoring and safety inspections. Cloud-Based Scent Intelligence: AI Nose-generated data will be integrated into cloud analytics platforms, offering insights for smart factories, healthcare, and security applications. Maintenance & Sensor Optimization: Ongoing servicing, software updates, and sensor calibration will ensure long-term reliability and accuracy. From Concept to Reality: The Roadmap to a Smarter Robot This collaboration will advance through a structured development plan designed to bring AI-powered olfaction to robotics: Seamless Technology Integration & Prototyping: Ainos and ugo will merge AI Nose with ugo robots and conduct initial performance testing. Real-World Pilot Deployments: The companies will validate the integrated solution in industries such as semiconductor manufacturing and public safety. AI Optimization & Performance Enhancement: System performance and AI models will be refined based on real-world data. Global Commercialization & Market Expansion: Ainos and ugo will scale the deployment of AI Nose-enabled robots worldwide. Empowering Industries and Addressing Labor Shortages with Intelligent Automation Beyond its commercial value, this collaboration will help address one of the most pressing challenges faced by industries worldwide: the growing labor shortage in critical sectors. Manufacturing & Industrial Safety: Skilled workers are increasingly difficult to find, and ensuring workplace safety remains a top priority. AI Nose-equipped ugo robots will take on hazardous inspection tasks, reducing risks and allowing human workers to focus on higher-value roles. Security & Public Safety: From airports to industrial sites, there is an increasing need for security personnel to handle safety threats. AI Nose-integrated robots will provide continuous, automated surveillance, enhancing security operations without additional staffing burdens. Healthcare & Elderly Care: The demand for healthcare services is surging due to aging populations, while shortages of medical and caregiving staff continue to grow. AI Nose-enabled robots will assist in monitoring patient health, detecting infections early, and supporting hygiene management in hospitals and elderly care facilities. By combining AI-powered scent detection with autonomous robotics, Ainos and ugo will help industries improve efficiency, reduce operational costs, and enhance workplace safety-while addressing the global labor gap. As the world faces increasing challenges in workforce shortages, sustainability, and public safety, this partnership will contribute to a smarter, healthier, and safer future. Ainos and ugo are committed to driving innovation that improves lives and supports industries in need of intelligent automation. About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name "Ainos" combines "AI" and "Nose" to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date. About ugo, Inc. ugo, Inc. is a developer of business digital transformation robots. "ugo" is a next-generation avatar robot that realizes a sustainable work style with humans and robots. By combining the advantages of both conventional simple remote-controlled robots and fully automated robots, it provides operations that fit the site. ugo was founded in 2018 and headquartered in Tokyo, Japan. For more information, visit website or its X (@ugo_robot). Keizai Group's "2024 Edition: Current Status and Future Prospects of the Worldwide Robot-Related Market - Service Robot Edition" published on January 15, 2024. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shenir@ SOURCE: Ainos, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
